{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"16.000","floor":"12.000"},"ipodate":{"start":"2018-07-20 00:00:00","end":"2018-07-25 00:00:00"},"minimumcapital":"16161.23","subscribed":"9.13","marketcap":"156.90億","H_marketcap":"--","pe":"--","codesrate":"40.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01672/LTN20180720034_C.pdf","ipopricing":"14.000","resultdate":"2018-07-31 00:00:00","enddate":"2018-07-25 00:00:00","listeddate":"2018-08-01 00:00:00","issuenumber":"22413.70萬","issuenumberhK":"2241.40萬","issuenumberother":"20172.30萬","grayprice":"14.18","sponsors":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,招商證券(香港)有限公司","raisemoney":"297600.00萬","use":"1、約30.0%或892.8百萬港元將用于我們核心產品線的持續研發；\n2、約25.0%或744.0百萬港元將用于戈諾衛及拉維達韋商業化；\n3、約15.0%或446.4百萬港元將用于尋求新在研藥物的引進許可，盡管我們截至最后實際可行日期尚未物色到任何潛在目標；\n4、約10.0%或297.6百萬港元將用于通過啟動及進行臨床試驗進行ASC21的研發；\n5、約10.0%或297.6百萬港元將用于支持我們的研發基礎設施及HBV及NASH發現階段兩個內部藥物計劃的早期開發；\n6、約10%或297.6百萬港元將用于我們的營運資金及作其他一般公司用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,招商證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,招商證券(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,招商證券(香港)有限公司","firstDayOpen":"14.80","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E01672","name":"歌禮制藥－Ｂ","fullname":"歌禮制藥有限公司"},"institutioninfo":{"principaloffice":"中國浙江省杭州市濱江區江漢路1785號雙城國際4幢18層","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"吳勁梓","secretary":"嚴洛鈞","telephone":"","substantialshareholders":"吳勁梓(49.3%),CBC 15(6.5%),CBC 12(5.9%),JJW11 Limited(5.8%)","principalactivities":"歌禮是一個一體化抗病毒平臺，專注于開發及商業化針對丙肝、HIV和乙肝的創新的、同類最佳的藥物。","website":"http://www.ascletis.com"},"managerinfo":[{"managername":"吳勁梓","post":"董事會主席、行政總裁兼執行董事","rankno":1},{"managername":"何凈島","post":"副總裁兼執行董事","rankno":2},{"managername":"Wei FU","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"GIC Private Limited","shareholding":"42,042,000.0","percentage":18.76,"ReleaseDate":"2019-03-01 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":18.76},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":514}